PFIZER INC (PFE) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-28..
- Stock-based compensation / revenue · 12 months: Value 1.49%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-28..
- Interest coverage · 12 months: Value (m); Formula and calculation Operating income ÷ reported interest expense..
Spending and interest coverage
Overview →Financial period ending 2026-06-28; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-28. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | 1.49% | Share-based compensation / revenue. Period ending 2026-06-28. $947.00M ÷ $63.70B × 100 ≈ 1.49% |
| Interest coverage · 12 months | (m) | Operating income ÷ reported interest expense. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | |
| Revenue | 63.70B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 947.00M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | (m) | |
| Interest expense · reported / estimated | 2.70B USD | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: Reported. Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-28 | (m) | $63.70B | $947.00M | (m) | $2.70B | (m) | 1.49% | (m) | Reported |
| 2026-03-29 | (m) | $63.31B | $901.00M | (m) | $2.69B | (m) | 1.42% | (m) | Reported |
| 2025-12-31 | (m) | $62.58B | $799.00M | (m) | $2.67B | (m) | 1.28% | (m) | Reported |
| 2025-09-28 | (m) | $62.78B | $751.00M | (m) | $2.70B | (m) | 1.20% | (m) | Reported |
| 2025-06-29 | (m) | $63.83B | $824.00M | (m) | $2.83B | (m) | 1.29% | (m) | Reported |
| 2025-03-30 | (m) | $62.46B | $827.00M | (m) | $2.96B | (m) | 1.32% | (m) | Reported |
| 2024-12-31 | (m) | $63.63B | $877.00M | (m) | $3.09B | (m) | 1.38% | (m) | Reported |
| 2024-09-29 | (m) | $51.79B | $821.00M | (m) | $3.04B | (m) | 1.59% | (m) | Reported |
| 2024-06-30 | (m) | $47.58B | $698.00M | (m) | $2.95B | (m) | 1.47% | (m) | Reported |
| 2024-03-31 | (m) | $47.31B | $640.00M | (m) | $2.68B | (m) | 1.35% | (m) | Reported |
| 2023-12-31 | (m) | $50.91B | $525.00M | (m) | $2.21B | (m) | 1.03% | (m) | Reported |
| 2023-10-01 | (m) | $68.54B | $768.00M | (m) | $1.83B | (m) | 1.12% | (m) | Reported |
| 2023-07-02 | (m) | $77.94B | $752.00M | (m) | $1.45B | (m) | 0.96% | (m) | Reported |
| 2023-04-02 | (m) | $92.95B | $891.00M | (m) | $1.23B | (m) | 0.96% | (m) | Reported |
| 2022-12-31 | (m) | $100.33B | $872.00M | (m) | $1.24B | (m) | 0.87% | (m) | Reported |
| 2022-10-02 | (m) | $99.88B | $1.00B | (m) | $1.24B | (m) | 1.01% | (m) | Reported |
| 2022-07-03 | (m) | $101.28B | $1.16B | (m) | $1.25B | (m) | 1.15% | (m) | Reported |
| 2022-04-03 | (m) | $92.43B | $1.10B | (m) | $1.28B | (m) | 1.19% | (m) | Reported |
| 2021-12-31 | (m) | $81.29B | $1.18B | (m) | $1.29B | (m) | 1.45% | (m) | Reported |
| 2021-10-03 | (m) | $69.34B | $975.00M | (m) | $1.32B | (m) | 1.41% | (m) | Reported |
| 2021-07-04 | (m) | $55.52B | $906.00M | (m) | $1.34B | (m) | 1.63% | (m) | Reported |
| 2021-04-04 | (m) | $46.41B | $871.00M | (m) | $1.40B | (m) | 1.88% | (m) | Reported |
| 2020-12-31 | (m) | $41.91B | $756.00M | (m) | $1.45B | (m) | 1.80% | (m) | Reported |
| 2020-09-27 | (m) | $48.65B | $762.00M | (m) | $1.59B | (m) | 1.57% | (m) | Reported |
| 2020-06-28 | (m) | $49.20B | $592.00M | (m) | $1.59B | (m) | 1.20% | (m) | Reported |
| 2020-03-29 | (m) | $50.66B | $597.00M | (m) | $1.60B | (m) | 1.18% | (m) | Reported |
| 2019-12-31 | (m) | $51.75B | $718.00M | (m) | $1.57B | (m) | 1.39% | (m) | Reported |
| 2019-09-29 | (m) | $53.04B | $715.00M | (m) | $1.53B | (m) | 1.35% | (m) | Reported |
| 2019-06-30 | (m) | $53.66B | $954.00M | (m) | $1.43B | (m) | 1.78% | (m) | Reported |
| 2019-03-31 | (m) | $53.86B | $952.00M | (m) | $1.37B | (m) | 1.77% | (m) | Reported |
| 2018-12-31 | (m) | $53.65B | $949.00M | (m) | $1.32B | (m) | 1.77% | (m) | Reported |
| 2018-09-30 | (m) | (m) | $927.00M | (m) | $1.28B | (m) | (m) | (m) | Reported |
| 2018-07-01 | (m) | (m) | $831.00M | (m) | $1.28B | (m) | (m) | (m) | Reported |
| 2018-04-01 | (m) | (m) | $804.00M | (m) | $1.27B | (m) | (m) | (m) | Reported |
| 2017-12-31 | (m) | (m) | $840.00M | (m) | $1.27B | (m) | (m) | (m) | Reported |
| 2017-10-01 | (m) | (m) | $754.00M | (m) | $1.24B | (m) | (m) | (m) | Reported |
| 2017-07-02 | (m) | (m) | $692.00M | (m) | $1.21B | (m) | (m) | (m) | Reported |
| 2017-04-02 | (m) | (m) | $766.00M | (m) | $1.19B | (m) | (m) | (m) | Reported |
| 2016-12-31 | (m) | (m) | $691.00M | (m) | $1.19B | (m) | (m) | (m) | Reported |
| 2016-10-02 | (m) | (m) | $713.00M | (m) | $1.22B | (m) | (m) | (m) | Reported |
| 2016-07-03 | (m) | (m) | $709.00M | (m) | $1.21B | (m) | (m) | (m) | Reported |
| 2016-04-03 | (m) | (m) | $650.00M | (m) | $1.20B | (m) | (m) | (m) | Reported |
| 2015-12-31 | (m) | (m) | $669.00M | (m) | $1.20B | (m) | (m) | (m) | Reported |
| 2015-09-27 | (m) | (m) | $650.00M | (m) | $1.22B | (m) | (m) | (m) | Reported |
| 2015-06-28 | (m) | (m) | $652.00M | (m) | $1.28B | (m) | (m) | (m) | Reported |
| 2015-03-29 | (m) | (m) | $605.00M | (m) | $1.35B | (m) | (m) | (m) | Reported |
| 2014-12-31 | (m) | (m) | $586.00M | (m) | $1.36B | (m) | (m) | (m) | Reported |
| 2014-09-28 | (m) | (m) | $529.00M | (m) | $1.35B | (m) | (m) | (m) | Reported |
| 2014-06-29 | (m) | $50.33B | $512.00M | (m) | $1.35B | (m) | 1.02% | (m) | Reported |
| 2014-03-30 | (m) | $50.53B | $477.00M | (m) | $1.36B | (m) | 0.94% | (m) | Reported |
| 2013-12-31 | (m) | $51.58B | $523.00M | (m) | $1.41B | (m) | 1.01% | (m) | Reported |
| 2013-09-29 | (m) | $56.25B | $537.00M | (m) | $1.44B | (m) | 0.95% | (m) | Reported |
| 2013-06-30 | (m) | $56.56B | $526.00M | (m) | $1.48B | (m) | 0.93% | (m) | Reported |
| 2013-03-31 | (m) | $57.60B | $540.00M | (m) | $1.52B | (m) | 0.94% | (m) | Reported |
| 2012-12-31 | (m) | $58.99B | $481.00M | (m) | $1.52B | (m) | 0.82% | (m) | Reported |
| 2012-09-30 | (m) | $62.23B | $434.00M | (m) | $1.55B | (m) | 0.70% | (m) | Reported |
| 2012-07-01 | (m) | $64.86B | $422.00M | (m) | $1.59B | (m) | 0.65% | (m) | Reported |
| 2012-04-01 | (m) | $66.33B | $427.00M | (m) | $1.61B | (m) | 0.64% | (m) | Reported |
| 2011-12-31 | (m) | $67.42B | $419.00M | (m) | $1.68B | (m) | 0.62% | (m) | Reported |
| 2011-10-02 | (m) | $68.24B | $401.00M | (m) | $1.75B | (m) | 0.59% | (m) | Reported |
| 2011-07-03 | (m) | $67.22B | $406.00M | (m) | $1.75B | (m) | 0.60% | (m) | Reported |
| 2011-04-03 | (m) | $67.73B | $389.00M | (m) | $1.74B | (m) | 0.57% | (m) | Reported |
| 2010-12-31 | (m) | $67.81B | $405.00M | (m) | $1.80B | (m) | 0.60% | (m) | Reported |
| 2010-10-03 | (m) | $66.78B | $442.00M | (m) | (m) | (m) | 0.66% | (m) | (m) |
| 2010-07-04 | (m) | $62.23B | $423.00M | (m) | (m) | (m) | 0.68% | (m) | (m) |
| 2010-04-04 | (m) | $55.89B | $416.00M | (m) | (m) | (m) | 0.74% | (m) | (m) |
| 2009-12-31 | (m) | $50.01B | $349.00M | (m) | (m) | (m) | 0.70% | (m) | (m) |
| 2009-09-27 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-06-28 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-03-29 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | $48.30B | $384.00M | (m) | (m) | (m) | 0.80% | (m) | (m) |
| 2008-09-28 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-06-29 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2007-12-31 | (m) | $48.42B | $437.00M | (m) | (m) | (m) | 0.90% | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |